Can AI predict who will respond to liver cancer drugs?

NCT ID NCT07495735

Recruiting now Knowledge-focused Sponsor: First Affiliated Hospital of Wenzhou Medical University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 05, 2026 · Updated 3 times

Summary

This study will use artificial intelligence to analyze CT scans and medical data from 400 liver cancer patients to predict who will respond to a common drug combination (atezolizumab and bevacizumab). The goal is to create a non-invasive tool that helps doctors choose the best treatment for each patient, avoiding ineffective therapies. The study is observational, meaning it looks back at existing patient data rather than testing a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to a non-invasive AI tool that helps doctors identify which liver cancer patients are most likely to benefit from a standard drug combination, avoiding unnecessary treatment.
What could go wrong: This is an observational study using past data, not a treatment trial. The AI model may not work as well in real-world settings or for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATEZOLIZUMAB AND BEVACIZUMAB IN HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATEZOLIZUMAB AND BEVACIZUMAB IN HEPATOCELLULAR CARCINOMA HCC - HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

First Affiliated Hospital of Wenzhou Medical University
RECRUITING

Wenzhou, Zhejiang, 325000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.